06:04 AM EDT, 05/01/2026 (MT Newswires) -- Astrazeneca (AZN) said Thursday that the US Food and Drug Administration's Oncologic Drugs Advisory Committee has recognized a favorable benefit risk profile for Truqap in combination with abiraterone and androgen deprivation therapy for the treatment of patients with prostate cancer.

The specific indication is for PTEN-deficient metastatic hormone-sensitive prostate cancer, the company said.

The company said the committee voted 7 to 1, with 1 member abstaining, the company said.

The decision was based on a phase 3 clinical trial that showed a 19% reduction in the risk of radiographic disease progression or death and an improvement in median radiographic progression-free survival of 7.5 months compared with treatment with abiraterone and ADT with a placebo, the company said.